{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:18:52Z","timestamp":1760746732030,"version":"build-2065373602"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2023 Annual Corps Guiding Science and Technology Plan Project of Shihezi University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03743-1","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:18:49Z","timestamp":1760699929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The expression of miR-381-3p in acute myeloid leukemia and its effect on corresponding cell proliferation and apoptosis"],"prefix":"10.1007","volume":"16","author":[{"given":"Jiali","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"5","key":"3743_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/jco.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, L\u00f6wenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29(5):487\u201394. https:\/\/doi.org\/10.1200\/jco.2010.30.1820.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"2","key":"3743_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015;65(2):87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262.","journal-title":"Cancer J Clin"},{"issue":"9","key":"3743_CR3","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3109\/10428194.2013.869802","volume":"55","author":"Y Li","year":"2014","unstructured":"Li Y, Zhu B. Acute myeloid leukemia with DNMT3A mutations. Leuk Lymphoma. 2014;55(9):2002\u201312. https:\/\/doi.org\/10.3109\/10428194.2013.869802.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"3743_CR4","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","volume":"120","author":"U Creutzig","year":"2012","unstructured":"Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi SC, Sung L, Stary J, Zwaan CM, Kaspers GJ, Reinhardt D. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187\u2013205. https:\/\/doi.org\/10.1182\/blood-2012-03-362608.","journal-title":"Blood"},{"issue":"2","key":"3743_CR5","doi-asserted-by":"publisher","first-page":"e83727","DOI":"10.1371\/journal.pone.0083727","volume":"9","author":"V Galli","year":"2014","unstructured":"Galli V, Guzman F, de Oliveira LF, Loss-Morais G, K\u00f6rbes AP, Silva SD, Margis-Pinheiro MM, Margis R. Identifying MicroRNAs and transcript targets in Jatropha seeds. PLoS ONE. 2014;9(2):e83727. https:\/\/doi.org\/10.1371\/journal.pone.0083727.","journal-title":"PLoS ONE"},{"issue":"5","key":"3743_CR6","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1002\/jcp.27486","volume":"234","author":"K Saliminejad","year":"2019","unstructured":"Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of micrornas: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451\u201365. https:\/\/doi.org\/10.1002\/jcp.27486.","journal-title":"J Cell Physiol"},{"issue":"12","key":"3743_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12032-020-01435-0","volume":"37","author":"PK Parizi","year":"2020","unstructured":"Parizi PK, Yarahmadi F, Tabar HM, Hosseini Z, Sarli A, Kia N, Tafazoli A, Esmaeili SA. MicroRNAs and target molecules in bladder cancer. Medical oncology (Northwood. Lond England). 2020;37(12):118. https:\/\/doi.org\/10.1007\/s12032-020-01435-0.","journal-title":"Lond England)"},{"key":"3743_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051723","author":"Z Ali Syeda","year":"2020","unstructured":"Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21051723.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3743_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","volume":"302","author":"B Zhang","year":"2007","unstructured":"Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1\u201312. https:\/\/doi.org\/10.1016\/j.ydbio.2006.08.028.","journal-title":"Dev Biol"},{"key":"3743_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111455","author":"S Sur","year":"2019","unstructured":"Sur S, Steele R, Shi X, Ray RB. miRNA-29b inhibits prostate tumor growth and induces apoptosis by increasing Bim expression. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8111455.","journal-title":"Cells"},{"key":"3743_CR11","doi-asserted-by":"publisher","first-page":"1482927","DOI":"10.3389\/fgene.2024","volume":"15","author":"Y Jing","year":"2024","unstructured":"Jing Y, Huang X, Wang Y, Wang J, Li Y, Yelihamu D, Guo C. Diagnostic value of 5 miRNAs combined detection for breast cancer. Front Genet. 2024;15:1482927. https:\/\/doi.org\/10.3389\/fgene.2024.","journal-title":"Front Genet."},{"issue":"1","key":"3743_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12672-025-01990-w","volume":"16","author":"X Huang","year":"2025","unstructured":"Huang X, Wang Y, Wang J, Jing Y, Dilraba E, Li Y, Guo C. Association of DBNDD1 with prognostic and immune biomarkers in invasive breast cancer. Discov Oncol. 2025;16(1):218. https:\/\/doi.org\/10.1007\/s12672-025-01990-w.","journal-title":"Discov Oncol"},{"key":"3743_CR13","doi-asserted-by":"publisher","first-page":"657650","DOI":"10.3389\/fonc.2021.657650","volume":"11","author":"W Zhang","year":"2021","unstructured":"Zhang W, Li X, Zhang W, Lu Y, Lin W, Yang L, Zhang Z, Li X. The LncRNA CASC11 promotes colorectal cancer cell proliferation and migration by adsorbing miR-646 and miR-381-3p to upregulate their target RAB11FIP2. Front Oncol. 2021;11:657650. https:\/\/doi.org\/10.3389\/fonc.2021.657650.","journal-title":"Front Oncol"},{"issue":"1","key":"3743_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13046-022-02545-5","volume":"41","author":"D Jin","year":"2022","unstructured":"Jin D, Guo J, Wu Y, Chen W, Du J, Yang L, Wang X, Gong K, Dai J, Miao S, Li X, Su G. Correction: Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis. J Experimental Clin Cancer Research: CR. 2022;41(1):339. https:\/\/doi.org\/10.1186\/s13046-022-02545-5.","journal-title":"J Experimental Clin Cancer Research: CR"},{"issue":"18","key":"3743_CR15","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.1002\/cam4.2630","volume":"8","author":"J Hu","year":"2019","unstructured":"Hu J, Wu X, Yang C, Rashid K, Ma C, Hu M, Ding Q, Jiang H. Anticancer effect of Icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C. Cancer Med. 2019;8(18):7833\u201345. https:\/\/doi.org\/10.1002\/cam4.2630.","journal-title":"Cancer Med"},{"key":"3743_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/ott.S223321","volume":"13","author":"H Mi","year":"2020","unstructured":"Mi H, Wang X, Wang F, Li L, Zhu M, Wang N, Xiong Y, Gu Y. SNHG15 contributes to cisplatin resistance in breast cancer through sponging miR-381. OncoTargets Therapy. 2020;13:657\u201366. https:\/\/doi.org\/10.2147\/ott.S223321.","journal-title":"OncoTargets Therapy"},{"issue":"2","key":"3743_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/gcc.22128","volume":"53","author":"G Papp","year":"2014","unstructured":"Papp G, Krausz T, Stricker TP, Szendr\u0151i M, S\u00e1pi Z. SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on both mRNA and protein levels. Genes Chromosomes Cancer. 2014;53(2):168\u201376. https:\/\/doi.org\/10.1002\/gcc.22128.","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"3743_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3349\/ymj.2019.60.8.720","volume":"60","author":"Y Li","year":"2019","unstructured":"Li Y, Sun H, Guan J, Ji T, Wang X. Serum microRNA-381: A potential marker for early diagnosis of gastric cancer. Yonsei Med J. 2019;60(8):720\u20136. https:\/\/doi.org\/10.3349\/ymj.2019.60.8.720.","journal-title":"Yonsei Med J"},{"issue":"12","key":"3743_CR19","first-page":"11610","volume":"10","author":"T Huang","year":"2017","unstructured":"Huang T, Yi D, Xu L, Bu E, Zhu C, Sang J, Zhang Y. Downregulation of miR-381 is associated with poor prognosis in papillary thyroid carcinoma. Int J Clin Exp Pathol. 2017;10(12):11610\u20136.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"3743_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3892\/ijo.2018.4646","volume":"54","author":"Z Fang","year":"2019","unstructured":"Fang Z, Zhong M, Wang Y, Yuan X, Guo H, Yao Y, Feng M, Chen J, Xiong J, Xiang X. miR-381 and miR-489 suppress cell proliferation and invasion by targeting CUL4B via the Wnt\/\u03b2-catenin pathway in gastric cancer. Int J Oncol. 2019;54(2):733\u201343. https:\/\/doi.org\/10.3892\/ijo.2018.4646.","journal-title":"Int J Oncol"},{"issue":"12","key":"3743_CR21","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.26355\/eurrev_201806_15264","volume":"22","author":"W Kong","year":"2018","unstructured":"Kong W, Yang L, Li PP, Kong QQ, Wang HY, Han GX, Wang QB. MiR-381-3p inhibits proliferation, migration and invasion by targeting LRP6 in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(12):3804\u201311. https:\/\/doi.org\/10.26355\/eurrev_201806_15264.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03743-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03743-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03743-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:18:50Z","timestamp":1760699930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03743-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3743"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03743-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (approval number 2203) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.Written informed consent was obtained from legally authorized representatives (LARs) of all minor participants under 18 years of age. Additionally, LARs provided a signed statement confirming that assent was appropriately sought from the minors, with research participation decisions made in accordance with the minors\u2019 best interests.This study was approved by the Ethics Committee of Science and Technology of The First Affiliated Hospital of Shihezi University (Approval No. KJ2024-262-01) on 15 May 2024.Patient samples were collected retrospectively (2014\u20132016), and ethical approval was obtained in May 2024 for secondary analysis of anonymized data in compliance with national regulations and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1907"}}